(3.239.33.139) 您好!臺灣時間:2021/03/08 18:22
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:林琨棟
研究生(外文):Kuen-Dong Lin
論文名稱:台灣戒菸門診服務計畫之投資報酬率分析
論文名稱(外文):The Return on Investment of Smoking Cessation Outpatient Clinic Program in Taiwan
指導教授:湯澡薰湯澡薰引用關係
口試委員:蒲若芳許玫玲
口試日期:2015-06-22
學位類別:碩士
校院名稱:臺北醫學大學
系所名稱:醫務管理學研究所
學門:商業及管理學門
學類:醫管學類
論文種類:學術論文
論文出版年:2015
畢業學年度:103
語文別:中文
論文頁數:367
中文關鍵詞:菸害防治戒菸投資報酬率健保資料庫
外文關鍵詞:Tobacco controlsmoking cessationReturn on investmentNational Health Insurance Research Database
相關次數:
  • 被引用被引用:0
  • 點閱點閱:25
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
論文名稱:台灣戒菸門診服務計畫之投資報酬率分析
研究所名稱:臺北醫學大學醫務管理系碩士班
研究生姓名:林琨棟
指導教授:湯澡薰 臺北醫學大學醫務管理學系暨研究所 教授
研究目的
本研究擬針對2003年1月至2012年12月期間,實施之「門診戒菸治療服務」,藉由計算此計畫的直接成本,與加入計畫而戒菸成功者之效益,從政府的觀點,推估此計畫的投資報酬率,藉由量化的財務數字,幫助政策決策者了解,是否值得繼續投資此項政策。
研究方法
成本部分使用國健署公布之政府預算書中,戒菸門診計畫相關之預算費用。效益部分,分為因戒菸而節省的醫療成本,及因戒菸避免的死亡成本。效益計算上,使用2003-2012年之健保資料庫抽樣檔,搭配政府官方統計資料(如吸菸盛行率、每月薪資…等),及各種流行病學的文獻數據。最後,結合推算的成本與效益,轉換為淨利益及投資報酬率。成本和效益以通貨膨脹及折現率調整,並進行敏感度分析,以了解各參數的不確定性及結果的穩定性。
結果
此門診計畫於2003-2012年之每年預算成本,介於0.97億至2.06億元間。每年因戒菸而造成的醫療成本節省,介於4065萬及2.56億元,而因戒菸而避免的死亡成本,則為11.9億及59.4億元。整體而言,每投資一塊錢,可回收11.3到52.5元。
結論
結果顯示,從政府的觀點來看,此十年間國健署對此計畫的投資,是具成本效益的,而全面性地推廣門診戒菸治療,可以造成大量的成本節省,值得政府未來繼續投資。
Title of thesis: The Return on Investment of Smoking Cessation Outpatient Clinic Program in Taiwan
Author: Kuen-Dong Lin
Thesis advised by: Chao-Hsuin Tang, Ph.D
Objectives: This study aims to evaluate the smoking cessation outpatient clinic program in Taiwan during 2003-2012 by return on investment analysis from the government’s perspective.
Methods: Administrative data from Health Promotion Administration, Ministry of Health and Welfare was used to estimate annual budget costs of the program from 2003 to 2012. The benefit data were collected from Nation Health Insurance Research database released from the National Health Research Institute, Adult Smoking Behavior Surveys released by Health Promotion Administration, and several epidemiology related literatures, to estimate the medical costs and mortality costs averted by smoking cessation. Estimated costs and benefits were combined together to calculate the net benefit and return on investment to assess whether the outpatient program is worth investing. All costs and benefit were inflation and discount adjusted. Sensitivity analysis were performed to account for the uncertainty of parameters.
Results: Administrative data showed that, program costs including pharmacotherapy, counseling, tracking, physician training courses and promotion costs, ranged about 97-206million NT dollars per year. Medical costs savings were about 40.7 to 256 million NT dollars per year. Mortality costs averted were estimated to be about 1.19 to 5.94 billion NT dollars per year. Every 1$ dollar in program costs was associated with about $11.3 to $52.5 NT dollars in costs savings annually during 2003-2012.
Conclusions: These results suggest that an investment in the smoking cessation outpatient clinic program was cost-beneficial from government’s perspective. A comprehensive tobacco cessation clinic program may result in substantial costs savings.
中文摘要 I
Abstract III
目 錄 V
表 目 錄 VII
圖 目 錄 XXIII
第一章 緒論 1
第一節 研究動機與背景 1
第二節 研究目的及研究問題 3
第二章 文獻探討 4
第一節 菸害相關流行病學概況 4
第二節 尼古丁成癮及戒菸治療 19
第三節 戒菸門診服務 23
第四節 經濟評估種類 26
第五節 菸害相關之成本及效益 31
第六節 研究現況探討 34
第三章 研究材料與方法 36
第一節 研究架構 36
第二節 研究設計 38
第三節 研究對象及操作型定義 43
第四節 統計分析 54
第四章 研究結果 56
第一節 描述性統計分析 56
第二節 成本分析 57
第三節 戒菸後醫療成本節省分析 58
第四節 死亡成本節省分析 71
第五節 淨利益及投資報酬率分析 75
第六節 敏感度分析 76
第五章 討論 339
第一節 研究資料完整性討論 339
第二節 研究結果討論 342
第三節 敏感度分析討論 345
第四節 研究限制 346
第六章 結論與建議 347
第一節 結論 347
第二節 建議 348
附錄 355
中文部分
1.台灣省菸酒公賣局(1996)。民國六十年至民國八十五年之台灣地區菸酒市場調查總報告。
2.李蘭、潘怜燕(2000):台灣地區成年人之吸菸率與吸菸行為:八十八年度之全國性調查。中華衛誌;19:423-36
3.李玉春、黃雅慧(2003): 國民健康局門診戒菸計畫之成本效益分析。
4.行政院衛生福利部國民健康署(2012)。2012台灣菸害防制年報。2014年12月1日,取自國民健康署網站:http://tobacco.hpa.gov.tw/
5.行政院衛生福利部國民健康署(2014)。民國九十三年至民國一百年成年人吸菸行為調查fact sheet。2014年12月1日,取自國民健康署網站:http://tobacco.hpa.gov.tw/
6.行政院衛生福利部國民健康署(2014)。戒菸治療教育課程基本教材。2014年12月1日,取自國民健康署網站:http://tobacco.hpa.gov.tw/
7.戒菸管理中心(2014)。戒菸門診服務概況統計。2014年12月1日,取自戒菸管理中心網站:http://ttc.hpa.gov.tw/quit/Default_main.asp
8.財團法人國家衛生研究院(2014),2001年國民健康訪問調查結果報告。2014年12月1日,取自http://nhis.nhri.org.tw/2001download.html
9.財團法人國家衛生研究院(2014)。全民健康保險研究資料庫資料清單。2014年12月1日,取自財團法人國家衛生研究院網站: http://nhird.nhri.org.tw/date_03.php
10.財團法人醫藥品查驗中心(2014)。藥物經濟評估方法學指南 – 2014年12月1日,取自財團法人醫藥品查驗中心網站:http://www2.cde.org.tw/FAQ/HTA/Pages/醫療科技評估.aspx

英文部分
1.Altman, D. G., Flora, J. A., Fortmann, S. P., & Farquhar, J. W. (1987). The cost-effectiveness of three smoking cessation programs. American Journal of Public Health, 77(2), 162-165.
2.Australian Institute of Health and Welfare 2001 National Drug Strategy Household Survey: Detailed Findings. Drug Statistics Series No. 11. 2002. AIHW Cat. No. PHE-41.
3.Centers for Disease Control and Prevention (2009) Adult cigarette smoking in the United States: current estimate. Retrieved December 1, 2014, from http://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm. Accessed 2011 Aug 05.
4.Centers for Disease Control and Prevention (2009) State-specific smoking attributable mortality and years of potential life lost—United States, 2000–2004. MMWR 58(02): 29–33.
5.Centers for Disease Control and Prevention (2010) Vital signs: Current cigarette smoking among adults aged $18 years—United States, 2009. MMWR 59(35): 1135–1140.
6.Clairns, J.(2001). Discounting in economic evaluation. In: Drummond, M. and McGuire, A.(eds). Economic Evaluation in Health Care: Merging Theory with Practice. Oxford University Press
7.Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-9.
8.Dilley, J. A., Harris, J. R., Boysun, M. J., & Reid, T. R. (2012). Program, policy, and price interventions for tobacco control: quantifying the return on investment of a state tobacco control program. American Journal of Public Health, 102(2), e22-e28.
9.Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years'' observations on male British doctors. BMJ. 2004;328:1519.
10.Fiore, M. (2008). Treating tobacco use and dependence: 2008 update: Clinical practice guideline. DIANE Publishing.
11.Jackson, Kenneth C., et al. "An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation." Journal of occupational and environmental medicine 49.4 (2007): 453-460.
12.Chen, P. C., Lee, Y. C., Tsai, S. T., & Lai, C. K. (2011). A Cost–Benefit Analysis of the Outpatient Smoking Cessation Services in Taiwan From a Societal Viewpoint. Nicotine & Tobacco Research, ntr241.
13.Javitz, H. S., Swan, G. E., Zbikowski, S. M., Curry, S. J., McAfee, T. A., Decker, D., ... & Jack, L. M. (2004). Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer''s perspective. Value in Health, 7(5), 535-543.
14.Land, T., Rigotti, N. A., Levy, D. E., Paskowsky, M., Warner, D., Kwass, J. A., ... & Keithly, L. (2010). A longitudinal study of Medicaid coverage for tobacco dependence treatments in Massachusetts and associated decreases in hospitalizations for cardiovascular disease. PLoS medicine, 7(12), e1000375.
15.Liaw, K. M., & Chen, C. J. (1998). Mortality attributable to cigarette smoking in Taiwan: a 12-year follow-up study. Tobacco Control, 7(2), 141-148.
16.Lightwood, James M., and Stanton A. Glantz. "Short-term economic and health benefits of smoking cessation myocardial infarction and stroke." Circulation96.4 (1997): 1089-1096.
17.Peto R, Lopez AD. The future worldwide health effects of current smoking patterns. In: Koop CE, Pearson CE, Schwarz MR, eds. Critical issues in global health. New York, NY: Jossey-Bass; 2001.
18.Returns on investment in public health: an epidemiological and economic analysis prepared for the Department of Health and Ageing. Department of Health and Ageing, 2003.
19.Richard, P., West, K., & Ku, L. (2012). The return on investment of a Medicaid tobacco cessation program in Massachusetts. PloS one, 7(1), e29665.
20.Ruger, Jennifer Prah, and Karen M. Emmons. "Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review." Value in Health 11.2 (2008): 180-190.
21.Rumberger, J. S., Hollenbeak, C. S., & Kline, D. (2010). Potential costs and benefits of smoking cessation: an overview of the approach to state specific analysis.
22.Shearer, J., & Shanahan, M. (2006). Cost effectiveness analysis of smoking cessation interventions. Australian and New Zealand journal of public health, 30(5), 428-434.
23.Sheridan, D. P., Hornung, C. A., McCutcheon, E. P., & Wheeler, F. C. (1993). Demographic and educational differences in smoking in a tobacco-growing state. American journal of preventive medicine.
24.Shultz, J. M., Novotny, T. E., & Rice, D. P. (1991). Quantifying the disease impact of cigarette smoking with SAMMEC II software. Public Health Reports, 106(3), 326.
25.Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012). Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 11(11).
26.TOOLKIT, E. O. T. (2011). Assessment of the Economic Costs of Smoking.
27.Tsai, S. P., Wen, C. P., Hu, S. C., Cheng, T. Y., & Huang, S. J. (2005). Workplace smoking related absenteeism and productivity costs in Taiwan. Tobacco control, 14(suppl 1), i33-i37.
28.U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014
29.US Department of Health and Human Services. The health consequences of smoking—50 years of progress. A report of the Surgeon General. January 2014. http://www.surgeongeneral.gov/ (last accessed 22 July 2014).
30.Warner, K. E. (1997). Cost effectiveness of smoking-cessation therapies. Pharmacoeconomics, 11(6), 538-549.
31.Wen CP, Tsai SP, Chen CJ, Cheng TY, Tsai MC, Levy DT. Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios.
32.Wen CP, Tsai SP, Chen CJ, et al: The mortality risks of smokers in Taiwan. Part I: cause-specific mortality. Prev Med 2004; 39: 528-35.
33.Wen, C. P., Levy, D. T., Cheng, T. Y., Hsu, C. C., & Tsai, S. P. (2005). Smoking behaviour in Taiwan, 2001. Tobacco control, 14(suppl 1), i51-i55.
34.World Health Organization(2011). Economics of tobacco toolkit: assessment of the economic costs of smoking
35.World Health Organization(2014). Tobacco fact sheet. Retrieved December 1, 2014, from http://www.who.int/mediacentre/factsheets/fs339/en/
36.Yang, M.-C., Fann, C.-Y., Wen, C.-P., & Cheng, T. (2005). Smoking attributable medical expenditures, years of potential life lost, and the cost of premature death in Taiwan. Tobacco Control, 14(suppl 1), i62-i70.
電子全文 電子全文(本篇電子全文限研究生所屬學校校內系統及IP範圍內開放)
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔